Miloš Brkušanin

Prof. Dr. Miloš Brkušanin

Faculty of biology, University of Belgrade, Belgrade, Beograd, Serbia
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2013 in BioMed Research International
Verified
Journal Article
Open access
PDF file
DSDusanka Savic-Pavicevic
Dusanka Savic-Pavicevic
JMJelena Miladinović
Jelena Miladinović
MBMiloš Brkušanin
Miloš Brkušanin
SŠSaša Šviković
Saša Šviković
SDSvetlana Djurica
Svetlana Djurica
SRStanka Romac
Stanka Romac
Myotonic dystrophy type 1 (DM1) is the most common adult onset muscular dystrophy, presenting as a multisystemic disorder with extremely variable clinical manifestation, from asymptomatic adults to severely affected neonates. A striking anticipation and parental-gender effect upon transmission are distinguishing genetic features in DM1 pedigrees. It is an autosomal dominant hereditary disease associated with an unstable expansion of CTG repeats in the 3′-UTR of theDMPKgene, with the number of repeats ranging from 50 to several thousand. The number of CTG repeats broadly correlates with both the age-at-onset and overall severity of the disease. Expanded DM1 alleles are characterized by a remarkable expansion-biased and gender-specific germline instability, and tissue-specific, expansion-biased, age-dependent, and individual-specific somatic instability. Mutational dynamics in male and female germline account for observed anticipation and parental-gender effect in DM1 pedigrees, while mutational dynamics in somatic tissues contribute toward the tissue-specificity and progressive nature of the disease. Genetic test is routinely used in diagnostic procedure for DM1 for symptomatic, asymptomatic, and prenatal testing, accompanied with appropriate genetic counseling and, as recommended, without predictive information about the disease course. We review molecular genetics of DM1 with focus on those issues important for genetic testing and counseling.

27 August 2015 in Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
MBMiloš Brkušanin
Miloš Brkušanin
AKAna Kosać
Ana Kosać
VJVladimir M. Jovanović
Vladimir M. Jovanović
JPJovan Pesovic
Jovan Pesovic
GBGoran Brajušković
Goran Brajušković
DSDusanka Savic-Pavicevic
Dusanka Savic-Pavicevic
Spinal muscular atrophy (SMA) is caused by functional loss of the survival of motor neuron 1 (SMN1) gene. Despite genetic homogeneity, phenotypic variability indicates the involvement of disease modifiers. SMN1 is located in 5q13.2 segmental duplication, enriched in genes and prone to unequal rearrangements, which results in copy number polymorphism (CNP). We examined the influence of CNP of 5q13.2 genes and their joint effect on childhood-onset SMA phenotype. Multiplex ligation-dependent probe amplification (MLPA) was used to construct 5q13.2 alleles and assess copy number of the SMN2, small EDRK-rich factor 1A (SERF1A) and NLR family apoptosis inhibitory protein (NAIP) genes in 99 Serbian patients with SMN1 homozygous absence (23-type I, 37-type II and 39-mild type III) and 122 patients' parents. Spearman rank test was performed to test correlation of individual genes and SMA type. Generalized linear models and backward selection were performed to obtain a model explaining phenotypic variation with the smallest set of variables. 5q13.2 alleles most commonly associated with type I harbored large-scale deletions, while those detected in types II and III originated from conversion of SMN1 to SMN2. Inverse correlation was observed between SMN2, SERF1A and NAIP CNP and SMA type (P=2.2e−16, P=4.264e−10, P=2.722e−8, respectively). The best minimal model describing phenotypic variability included SMN2 (P<2e−16), SERF1A (P<2e−16) and their interaction (P=0.02628). SMN2 and SERF1A have a joint modifying effect on childhood-onset SMA phenotype.

15 March 2017 in European Journal of Human Genetics
Verified
Journal Article
Closed access
SPStojan Perić
Stojan Perić
JGJelena Nikodinović Glumac
Jelena Nikodinović Glumac
ATAna Töpf
Ana Töpf
DSDusanka Savic-Pavicevic
Dusanka Savic-Pavicevic
LPLauren Phillips
Lauren Phillips
VSVolker Straub
Volker Straub

13 January 2017 in Journal of Neural Transmission
Verified
Journal Article
Closed access
PDF file
JKJelena Karanović
Jelena Karanović
MIMaja Ivković
Maja Ivković
VJVladimir M. Jovanović
Vladimir M. Jovanović
SŠSaša Šviković
Saša Šviković
MPMaja Pantović-Stefanović
Maja Pantović-Stefanović
DSDusanka Savic-Pavicevic
Dusanka Savic-Pavicevic

Verified
Journal Article
Open access
PDF file
SJSuzana Matijašević Joković
Suzana Matijašević Joković
AKAleksandra Korac
Aleksandra Korac
SKSanja Kovacevic
Sanja Kovacevic
Ana DjordjevicAna Djordjevic
Ana Djordjevic
LFLidija Filipović
Lidija Filipović
GBGoran Brajušković
Goran Brajušković
Prostate-specific membrane antigen (PSMA) and caveolin-1 are membrane proteins that are overexpressed in prostate cancer (PCa) and are involved in tumor growth and increase in aggressiveness. The aim of the present study is therefore to evaluate PSMA and caveolin-1 proteins from plasma exosomes as effective liquid biopsy biomarkers for PCa. This study included 39 patients with PCa and 33 with benign prostatic hyperplasia (BPH). The shape and size of the exosomes were confirmed by transmission electron microscopy (TEM) and scanning electron microscopy (SEM) analysis. Immunogold analysis showed that PSMA is localized to the membrane of exosomes isolated from the plasma of both groups of participants. The relative protein levels of PSMA and caveolin-1 in the plasma exosomes of PCa and BPH patients were determined by Western blot analysis. The relative level of the analyzed plasma exosomal proteins was compared between PCa and BPH patients and the relevance of the exosomal PSMA and caveoin-1 level to the clinicopathological parameters in PCa was investigated. The analysis performed showed an enrichment of exosomal PSMA in the plasma of PCa patients compared to the exosomes of men with BPH. The level of exosomal caveolin-1 in plasma was significantly higher in PCa patients with high PSA levels, clinical-stage T3 or T4 and in the group of PCa patients with aggressive PCa compared to favorable clinicopathological features or tumor aggressiveness. Plasma exosomes may serve as a suitable object for the identification of potential biomarkers for the early diagnosis and prognosis of PCa as well as carriers of therapeutic agents in precision medicine of PCa treatment.

4 August 2022 in Genes
Verified
Journal Article
Open access
PDF file
AKAna Kosac
Ana Kosac
JPJovan Pesovic
Jovan Pesovic
LRLana Radenkovic
Lana Radenkovic
MBMiloš Brkušanin
Miloš Brkušanin
NRNemanja Radovanovic
Nemanja Radovanovic
VRVedrana Milic Rasic
Vedrana Milic Rasic
Background: Clinical course variability in Duchenne muscular dystrophy (DMD) is partially explained by the mutation location in the DMD gene and variants in modifier genes. We assessed the effect of the SPP1, CD40, and LTBP4 genes and DMD mutation location on loss of ambulation (LoA). Methods: SNPs in SPP1-rs28357094, LTBP4-rs2303729, rs1131620, rs1051303, rs10880, and CD40-rs1883832 were genotyped, and their effect was assessed by survival and hierarchical cluster analysis. Results: Patients on glucocorticoid corticosteroid (GC) therapy experienced LoA one year later (p = 0.04). The modifying effect of SPP1 and CD40 variants, as well as LTBP4 haplotypes, was not observed using a log-rank test and multivariant Cox regression analysis. Cluster analysis revealed two subgroups with statistical trends in differences in age at LoA. Almost all patients in the cluster with later LoA had the protective IAAM LTBP4 haplotype and statistically significantly fewer CD40 genotypes with harmful T allele and “distal” DMD mutations. Conclusions: The modifying effect of SPP1, CD40, and LTBP4 was not replicated in Serbian patients, although our cohort was comparable in terms of its DMD mutation type distribution, SNP allele frequencies, and GC-positive effect with other European cohorts. Cluster analysis may be able to identify patient subgroups carrying a combination of the genetic variants that modify LoA.